Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Investigating Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

NCT07011576 is registered in ClinicalTrials.gov with SCRI Development Innovations, LLC as lead sponsor.

NCT NCT07011576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07011576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Investigating Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
Lead sponsor
SCRI Development Innovations, LLC
Phase
Phase 2
Overall status
Recruiting
Start date
September 29, 2025
Completion date
June 30, 2027
Enrollment
60 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer, colorectal cancer, colorectal cancer (crc), rectal cancer